Clinical outcomes
The percentage in an event trial counts a different kind of change. The people and the composite outcome give that change its meaning.
SELECT
SELECT enrolled 17,604 adults with preexisting cardiovascular disease and overweight or obesity, without diabetes. Semaglutide reduced the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke compared with placebo: hazard ratio 0.80, with a 95% confidence interval of 0.72–0.90.
A composite joins several specified events into the trial’s main outcome. The direct observation of those events is the achievement that impresses me. The same result is reported as a 20% relative risk reduction; that percentage concerns the cardiovascular composite. It gives the discussion a different centre of gravity from a comparison of body-weight change.
The people studied had established cardiovascular disease. That qualification deserves the same prominence as the favourable finding. The comparison was with placebo, so this paper gives no direct semaglutide-versus-tirzepatide verdict for cardiovascular events.
FLOW
In FLOW, 3,533 participants had type 2 diabetes and chronic kidney disease. Semaglutide reduced major kidney-disease events compared with placebo: hazard ratio 0.76, with a 95% confidence interval of 0.66–0.88. The composite included kidney failure, at least a 50% decline in eGFR, or kidney or cardiovascular death. eGFR is an estimate of kidney filtration.
This result earns considerable respect from me. The endpoint concerns serious disease progression in a defined clinical population. It warrants a judgment of its own, rather than serving as a decorative footnote beneath a weight-loss percentage.
SELECT and FLOW also resist being merged into one universal “organ protection” claim. Their populations and composite outcomes differ. The specificity is useful: it tells the reader where the observed benefit was established.
STEP-HFpEF
STEP-HFpEF examined semaglutide in people with obesity-related heart failure with preserved ejection fraction. Compared with placebo, semaglutide improved heart-failure-related symptoms and physical limitations and produced greater weight loss.
Symptoms and physical limitations give the account another dimension. The burden of disease deserves attention alongside the occurrence of a specified event. This result concerns the symptom and limitation measures reported in that heart-failure population.
Taken together, these papers give semaglutide meaningful results against placebo on several outcomes. The SURMOUNT-5 weight-loss finding gives tirzepatide a direct comparative win on body weight. Each judgment remains intact. A final champion across all of these outcomes would require a contest these papers have not supplied.
Return to the direct comparison, or read the adverse findings alongside the benefits.